GSK plc (GLAXF)

OTCMKTS · Delayed Price · Currency is USD
21.74
+0.74 (3.50%)
Oct 8, 2025, 3:41 PM EDT
3.50%
Market Cap87.37B
Revenue (ttm)43.34B
Net Income (ttm)4.69B
Shares Outn/a
EPS (ttm)1.13
PE Ratio18.63
Forward PE9.26
Dividend0.82 (3.91%)
Ex-Dividend DateAug 14, 2025
Volume345
Average Volume4,670
Open21.74
Previous Close21.00
Day's Range21.74 - 21.74
52-Week Range15.54 - 22.85
Beta0.29
RSI56.78
Earnings DateOct 29, 2025

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange OTCMKTS
Ticker Symbol GLAXF
Full Company Profile

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP Financial Statements

News

Focus: US Health Secretary Kennedy speeds autism drug with GSK help

U.S. Health Secretary Robert F Kennedy Jr. could deliver a policy win for the Trump administration in just a few months after the Food and Drug Administration enlisted GSK to help it fast-track approv...

2 days ago - Reuters

Outgoing GSK boss Emma Walmsley takes swipe at Labour

Walmsley became the latest to speak out over a pricing regime that has infuriated the pharmaceutical sector.

4 days ago - This is Money

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

7 days ago - Evening Standard

Market Voices: Cook vs. Trump, ADP job data, GSK CEO on drug talks

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

7 days ago - Seeking Alpha

GSK's $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal

GSK's $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal

7 days ago - GuruFocus

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immuniz...

7 days ago - Business Wire

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

7 days ago - Benzinga

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

7 days ago - Benzinga

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ: ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies. Referred to as “Royalty Management Co” and “Biop...

8 days ago - Benzinga

GSK leadership shuffle: Luke Miels named CEO after Emma Walmsley exits; US tariffs test British pharma sector

GSK CEO Emma Walmsley will step down in January, with Luke Miels taking over amidst looming US tariffs on branded pharmaceutical imports. This leadership change comes as GSK navigates critical global ...

8 days ago - The Times of India

GSK Begins GBP 0.3 Bln Third Tranche Of GBP 2 Bln Share Buyback Programme

(RTTNews) - GSK plc (GSK, GSK.L), a biopharmaceutical company, on Tuesday said it has commenced the third tranche valued at up to 0.3 billion pounds of its previously announced 2 billion pounds share ...

8 days ago - Nasdaq

Emma Walmsley steadied GSK – but doubts linger over growth targets

The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenues GSK’s Emma Walmsley to step down as chief executive after eight years “I am a change agent,” declare...

9 days ago - The Guardian

GSK (GSK) Shares Rise as Luke Miels Announced as Future CEO

GSK (GSK) Shares Rise as Luke Miels Announced as Future CEO

9 days ago - GuruFocus

European stocks advance as pharma giants AstraZeneca and GSK notch gains

The U.K.'s FTSE 100 led gains on Monday.

9 days ago - CNBC

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Wal...

9 days ago - Benzinga

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.

9 days ago - Benzinga

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley

GSK stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year.

9 days ago - Investor's Business Daily

GSK (GSK) Announces Leadership Change as CEO Emma Walmsley Steps Down

GSK (GSK) Announces Leadership Change as CEO Emma Walmsley Steps Down

9 days ago - GuruFocus

Analyst: Miels was always number one candidate for GSK CEO

GSK CEO Emma Walmsley will step down in January after nine years at the helm of the British drugmaker.She will be replaced by the current chief commercial officer, Luke Miels. Emily Field, Head of Eur...

9 days ago - CNBC

GSK's Walmsley to step down early as insider Luke Miels named next CEO

GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday.

9 days ago - CNBC

GSK CEO Emma Walmsley to Step Down, Luke Miels to Succeed

GSK CEO Emma Walmsley to Step Down, Luke Miels to Succeed

9 days ago - GuruFocus